Analysis of phenylpiperazine-like stimulants in human hair as trimethylsilyl derivatives by gas chromatography–mass spectrometry

This publication has 19 references indexed in Scilit:

• Bioanalysis of New Designer Drugs
  Bioanalysis, 2010
• Investigation of the First Deaths in the United Kingdom Involving the Detection and Quantitation of the Piperazines BZP and 3-TFMPP
  Journal of Analytical Toxicology, 2008
• Piperazine designer drugs of abuse
  The Lancet, 2007
• N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’)
  Neuropsychopharmacology, 2004
• Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types
  Therapeutic Drug Monitoring, 2004
• Piperazine-Derived Designer Drug 1-(3-Chlorophenyl)piperazine (mCPP): GC-MS Studies on its Metabolism and its Toxicological Detection in Rat Urine Including Analytical Differentiation from its Precursor Drugs Trazodone and Nefazodone*
  Journal of Analytical Toxicology, 2003
• Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography–mass spectrometry
  Journal of Chromatography B, 2002
• Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market
  Forensic Science International, 2001
• High-performance liquid chromatographic assay with ultraviolet detection for the determination of etoperidone and two active metabolites, 5-(1-hydroxyethyl)etoperidone and 1-(3-chlorophenyl)piperazine, in plasma
  Journal of Chromatography B: Biomedical Sciences and Applications, 1991
• 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole
  Journal of Pharmacy and Pharmacology, 1982